Abstract
Glioma is regarded as the most prevalent malignant carcinoma of the central nervous system. Thus, the development of new therapeutic strategies targeting glioma is of significant clinical importance. Long non-coding RNAs (lncRNAs) are functional RNA molecules without a protein-coding function and are reportedly involved in the initiation and progression of glioma. Dysregulation of lncRNAs in glioma is due to activation of several signaling pathways, such as the BRD4-HOTAIR-β-catenin/PDCD4, p53-Hif-H19/IGF2 and CRNDE/mTOR pathways. Furthermore, microRNAs (miRNAs) such as miR-675 also interact with lncRNAs in glioma. Thus, exploring the mechanisms by which lncRNA control processes will be instrumental for devising new effective therapies against glioma.
Highlights
Glioma is the most common and aggressive malignant tumor of the central nervous system and has a high rate of recurrence and mortality [1]
We summarize the latest evidence for the roles of Long non-coding RNAs (lncRNAs) in regulating the biological behavior and the underlying mechanisms of glioma
Reports have demonstrated that lncRNAs exert significant biological functions in gliomas, including the initiation of malignancy, progression and other phenotypes
Summary
Glioma is the most common and aggressive malignant tumor of the central nervous system and has a high rate of recurrence and mortality [1]. Both studies confirmed the up-regulation of HOX transcript antisense RNA (HOTAIR) and colorectal neoplasia differentially expressed (CRNDE) in tumor samples. Another lncRNA, cancer-associated transcript 2 (CCAT2), was found to be up-regulated in glioma tissues and positively correlated with tumor stage.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call